21 research outputs found
A Prototype Ice-Melting Probe for Collecting Biological Samples from Cryogenic Ice at Low Pressure
LONG TERM EFFECT OF PERINDOPRIL ON CORONARY ATHEROSCLEROSIS PROGRESSION (FROM THE PERINDOPRIL'S PROSPECTIVE EFFECT ON CORONARY ATHEROSCLEROSIS BY ANGIOGRAPHY AND INTRAVASCULAR ULTRASOUND EVALUATION [PERSPECTIVE] STUDY).
The multicenter EUROPA trial of 12,218 patients showed that perindopril decreased adverse
clinical events in patients with established coronary heart disease. The PERSPECTIVE study,
a substudy of the EUROPA trial, evaluated the effect of perindopril on coronary plaque
progression as assessed by quantitative coronary angiography and intravascular ultrasound
(IVUS). In total 244 patients (mean age 57 years, 81% men) were included. Evaluable
paired quantitative coronary angiograms were obtained from 96 patients randomized to
perindopril and from 98 patients to placebo. Concomitant treatment at baseline consisted
of aspirin (90%), lipid-lowering agents (70%), and blockers (60%). The primary and
secondary end point was the difference of minimum and mean lumen diameters (quantitative
coronary angiography) or mean plaque cross-sectional area (IVUS) measured at
baseline and 3-year follow-up between the perindopril and placebo groups. After a median
follow-up of 3.0 years (range 1.9 to 4.1), no differences in change in quantitative coronary
angiographic or IVUS measurements were detected between the perindopril and placebo
groups (minimum and mean luminal diameters 0.07 0.4 vs 0.02 0.4 mm, p 0.34;
mean luminal diameter 0.05 0.2 vs 0.05 0.3 mm, p 0.89; mean plaque crosssectional
area 0.18 1.2 vs 0.02 1.2 mm2, p 0.48). In conclusion, we found no
progression in coronary artery disease by quantitative coronary angiography and IVUS
with long-term administration of perindopril or placebo, possibly because most patients
were on concomitant treatment with a statin
Recommandations de l’Académie nationale de médecine pour la prise en charge des patients après infarctus du myocarde
Pre-hypertension: how low to go and do drugs have a role?
People with pre-hypertension (high blood pressure but below the conventional threshold for intervention with antihypertensive drugs) undoubtedly have increased risk of cardiovascular and other complications. However, the vast majority has low absolute risk and whether treatment would be beneficial is uncertain. While pharmacotherapy has attractions from a public health perspective, clinicians and crucially those with pre-hypertension require robust evidence that drug treatment will lead to short term as well as long term gains. Any changes in recommendations should await adequately powered outcome studies which provide solid evidence of the magnitude of absolute risk reduction in treating pre-hypertension and assessment of the cost-effectiveness
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease
Aims The efficacy of angiotensin-converting enzyme (ACE)-inhibitors in stable coronary artery disease (CAD) may be increased by targeting the therapy to those patients most likely to benefit. However, these patients cannot be identified by clinical characteristics. We developed a genetic profile to predict the treatment benefit of ACE-inhibitors exist and to optimize therapy with ACE-inhibitors. Methods and resultsIn 8907 stable CAD patients participating in the randomized placebo-controlled EUROPA-trial, we analysed 12 candidate genes within the pharmacodynamic pathway of ACE-inhibitors, using 52 haplotype-tagging-single nucleotide polymorphisms (SNPs). The primary outcome was the reduction in cardiovascular mortality, non-fatal myocardial infarction, and resuscitated cardiac arrest during 4.2 years of follow-up. Multivariate Cox regression was performed with multiple testing corrections using permutation analysis. Three polymorphisms, located in the angiotensin-II type I receptor and bradykinin type I receptor genes, were significantly associated with the treatment benefit of perindopril after multivariate adjustment for confounders and correction for multiple testing. A pharmacogenetic score, combining these three SNPs, demonstrated a stepwise reduction of risk in the placebo group and a stepwise decrease in treatment benefit of perindopril with an increasing scores (interaction P < 0.0001). A pronounced treatment benefit was observed in a subgroup of 73.5 of the patients [hazard ratio (HR) 0.67; 95 confidence interval (CI) 0.56-0.79], whereas no benefit was apparent in the remaining 26.5 (HR 1.26; 95 CI 0.97-1.67) with a trend towards a harmful effe